Services · Fiscal year end Mar 31

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

2395

株式会社新日本科学

FIGI BBG000K9PFX02395.T2395 JPCorp. no. 9340001000031

Latest half-year results

First half · fiscal year to 2026-03 · filed 2025-11-07

For the first half of the fiscal year to 2026-03: Revenue ¥14.8 billion (+18.1% YoY), Ordinary income ¥1.6 billion (-11.0% YoY), Net income ¥1.1 billion (-20.3% YoY).

	This period	Year on year
Revenue	¥14.8bn	+18.1%
Ordinary profit	¥1.6bn	-11.0%
Net profit to owners	¥1.1bn	-20.3%

From the securities report on EDINET, which states no forecast. History via /v1/companies/2395/earnings-releases.

Financials

Japan GAAP · consolidated · fiscal year to 2026-03-31

Revenue: ¥32.5bn
Net income: ¥4.6bn
ROE: 11.0%
Equity ratio: 41.0%
Dividend / share: ¥50
Employees: 1,522

Revenue · ¥bn

Net income · ¥bn

Fiscal year	Revenue	Net income	Total assets	Net assets	ROE	EPS	Operating CF
2026-03-31	¥32.5bn	¥4.6bn	¥105.1bn	¥43.5bn	11.0%	¥109.69	¥8.3bn
2025-03-31	¥32.4bn	¥4.9bn	¥92.4bn	¥40.1bn	13.3%	¥118.29	¥7.0bn
2024-03-31	¥26.5bn	¥5.5bn	¥76.3bn	¥34.2bn	18.3%	¥132.86	¥2.1bn
2023-03-31	¥25.1bn	¥6.1bn	¥57.2bn	¥26.4bn	26.5%	¥145.56	¥4.0bn
2022-03-31	¥17.7bn	¥7.1bn	¥39.3bn	¥19.7bn	40.4%	¥171.2	¥6.0bn

Indicators

Computed by us from filings · fiscal year to 2026-03-31

Metric	Value	Percentile among listed companies
ROE, %	11	63.4
Ordinary margin	0.1793	87.5
Equity ratio, %	41	28.5
Revenue growth	0.0034	26.2
Net income growth	-0.0727	29.9
Operating cash flow / assets	0.0793	60.7

Policy-uncertainty measure0.00 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.

Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change −1.07pt in 90 days; 0.0% held by other listed companies.

Results wording balance: 0.00. Proprietary text method; it describes the wording only and does not interpret context.

Interest example: if all ¥40.8bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥204m, 2.5% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.

Via /v1/companies/2395/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them

Internal control, 2026-06-25: see filing 上記の評価の結果、当事業年度末日時点において、当社の財務報告に係る内部統制は有効であると判断した。 Filing

Segments, votes and tender offers

Stated in EDINET filings

Segments: Translational Research, CRO, Medipolis, US Asset Management, Other. /v1/companies/2395/segments

Latest voting result: 2026-06-26 · 定款の一部変更の件 · passed. /v1/companies/2395/voting

Ownership changes

All companies →

2026-10-07

Below 5%−1.07pt

Asset Management One Co., Ltd. cut holdings in SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (2395) to 3.97% from 5.04%, below the 5% threshold.

S100Z6H5Filer profile Original filing (PDF, Japanese)
2025-12-22

New 5% stake

Asset Management One Co., Ltd. disclosed a 5.04% stake in SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (2395), crossing the 5% reporting threshold.

S100XBRWFiler profile Original filing (PDF, Japanese)
2025-12-05

Increase+0.17pt

Sumitomo Mitsui DS Asset Management Company, Limited raised holdings in SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (2395) to 5.53% from 5.36%.

S100X8OUFiler profile Original filing (PDF, Japanese)
2025-09-05

New 5% stake

Sumitomo Mitsui DS Asset Management Company, Limited disclosed a 5.36% stake in SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (2395), crossing the 5% reporting threshold.

S100WN8IFiler profile Original filing (PDF, Japanese)
2024-06-04

Increase+2.46pt

Nagata and Company Inc. raised holdings in SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (2395) to 40.33% from 37.87%.

S100TJF9Filer profile Original filing (PDF, Japanese)
2023-12-27

Increase+0.12pt

Nagata and Company Inc. raised holdings in SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (2395) to 37.87% from 37.75%.

S100SHBTFiler profile Original filing (PDF, Japanese)
2023-06-07

Below 5%−1.19pt

Asset Management One Co., Ltd. cut holdings in SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (2395) to 3.93% from 5.12%, below the 5% threshold.

S100QW6OFiler profile Original filing (PDF, Japanese)
2023-01-20

New 5% stake

Asset Management One Co., Ltd. disclosed a 5.12% stake in SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (2395), crossing the 5% reporting threshold.

S100PZT2Filer profile Original filing (PDF, Japanese)
2022-04-22

Increase+0.08pt

Nagata and Company Inc. raised holdings in SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (2395) to 37.75% from 37.67%.

S100NXB8Filer profile Original filing (PDF, Japanese)

Trades by 5% holders

From the 60-day trade tables in 5% reports

Bought SoldHover a dot for the trade

Holder	Period	Net shares	Net % of shares	Avg. filed price	Range
Nagata and Company株式会社	2023-12-20 – 2024-05-28	+2,048,000	+4.92pt	¥1,464.5	¥1,307–1,622
individual filer	2023-12-20 – 2023-12-20	-1,024,000	−2.46pt	¥1,622	¥1,622–1,622

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/2395/trades.

5% filings

Large shareholding reports on 2395

Filed	Filer	Stake	Change	Stated purpose
2026-10-07	Asset Management One Co., Ltd.	3.97%	−1.07pt	—
2026-04-24	Nagata and Company Inc.	40.33%	0.00pt	management participation
2025-12-22	Asset Management One Co., Ltd.	5.04%	—	—
2025-12-05	Sumitomo Mitsui DS Asset Management Company, Limited	5.53%	+0.17pt	pure investment
2025-09-05	Sumitomo Mitsui DS Asset Management Company, Limited	5.36%	—	pure investment
2024-06-04	Nagata and Company Inc.	40.33%	+2.46pt	management participation
2023-12-27	Nagata and Company Inc.	37.87%	+0.12pt	management participation
2023-06-07	Asset Management One Co., Ltd.	3.93%	−1.19pt	—
2023-01-20	Asset Management One Co., Ltd.	5.12%	—	—
2022-04-22	Nagata and Company Inc.	37.75%	+0.08pt	management participation

Cross-shareholdings

From the annual report's status of shareholdings

Listed strategic holdings: 1 issues
Book value: ¥265m
Sold in the year: — — issues
Bought in the year: — — issues
Mutual, both reports: 0
Held by listed cos.: 0

Holds	Book value	Shares vs. prior year	Mutual
WOOJUNG BIO, Inc.	¥265m	0.0%	no

Purposes, all holdings and mutual flags via /v1/companies/2395/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2026-03-31

Shareholder	Shares	Ratio
Nagata and Company株式会社	16,788,000	40.33%
日本マスタートラスト信託銀行株式会社（信託口）	2,920,000	7.01%
株式会社日本カストディ銀行（信託口）	2,175,000	5.22%
individual holder	1,840,000	4.42%
individual holder	1,550,000	3.72%
一般社団法人メディポリス医学研究所	1,474,000	3.54%
individual holder	1,024,000	2.46%
野村證券株式会社	472,000	1.13%
モルガン・スタンレーＭＵＦＧ証券株式会社	398,000	0.96%
新日本科学従業員持株会	372,000	0.89%

U.S. funds holding 2395

SEC Form N-PORT, reports to 2026-07-31

22 U.S. funds held 1,098,079 shares worth $8.4m.

Fund	Shares	Value	% of fund	As of
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND VANGUARD STAR FUNDS	280,604	$2.2m	0.000%	2026-07-31
WisdomTree Japan Hedged Equity Fund WisdomTree Trust	194,500	$1.4m	0.019%	2026-06-30
VANGUARD DEVELOPED MARKETS INDEX FUND VANGUARD TAX-MANAGED FUNDS	187,921	$1.3m	0.000%	2026-06-30
VANGUARD FTSE ALL-WORLD EX-US SMALL-CAP INDEX FUND VANGUARD INTERNATIONAL EQUITY INDEX FUNDS	85,600	$0.7m	0.005%	2026-07-31
THE JAPANESE SMALL COMPANY SERIES DFA INVESTMENT TRUST CO	74,200	$0.6m	0.015%	2026-07-31

Up to 25 funds per stock via the API.

Get this as JSON

GET /v1/companies/2395
GET /v1/companies/2395/financials
GET /v1/companies/2395/details
GET /v1/companies/2395/segments
GET /v1/companies/2395/voting
GET /v1/companies/2395/tender-offers
GET /v1/companies/2395/indicators
GET /v1/companies/2395/earnings-releases
GET /v1/events?ticker=2395
GET /v1/companies/2395/trades         
GET /v1/companies/2395/cross-holdings 
GET /v1/companies/2395/brief

Plans from $9 a month · Documentation